Log In
BCIQ
Print this Print this
 

RSV F vaccine

  Manage Alerts
Collapse Summary General Information
Company Novavax Inc.
DescriptionRespiratory syncytial virus (RSV) vaccine targeting RSV viral fusion F protein formulated using recombinant nanoparticle technology
Molecular Target RSV F protein
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: Viral vaccine
Latest Stage of DevelopmentPhase III
Standard IndicationRespiratory syncytial virus (RSV)
Indication DetailsPrevent moderate to severe RSV-associated lower respiratory tract disease in older adults; Prevent respiratory syncytial virus (RSV) infection in infants via maternal immunization; Vaccinate against respiratory syncytial virus (RSV) infection; Vaccinate against respiratory syncytial virus (RSV) infection in healthy elderly subjects; Vaccinate infants against respiratory syncytial virus (RSV) infection via maternal immunization
Regulatory Designation U.S. - Fast Track (Prevent moderate to severe RSV-associated lower respiratory tract disease in older adults);
U.S. - Fast Track (Prevent respiratory syncytial virus (RSV) infection in infants via maternal immunization)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$2.0M

$2.0M

0


 Deals Details
Get a free BioCentury trial today